Premium
cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation
Author(s) -
Brunt Elizabeth,
Aishima Shinichi,
Clavien PierreAlain,
Fowler Kathryn,
Goodman Zachary,
Gores Gregory,
Gouw Annette,
Kagen Alex,
Klimstra David,
Komuta Mina,
Kondo Fukuo,
Miksad Rebecca,
Nakano Masayuki,
Nakanuma Yasuni,
Ng Irene,
Paradis Valerie,
Nyun Park Young,
Quaglia Alberto,
Roncalli Massimo,
Roskams Tania,
Sakamoto Michiie,
Saxena Romil,
Sempoux Christine,
Sirlin Claude,
Stueck Ashley,
Thung Swan,
Tsui W.M.S.,
Wang XinWei,
Wee Aileen,
Yano Hirohisa,
Yeh Matthew,
Zen Yoh,
ZucmanRossi Jessica,
Theise Neil
Publication year - 2018
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.29789
Subject(s) - terminology , medicine , hepatology , h&e stain , histopathology , consensus conference , pathology , general surgery , staining , philosophy , linguistics
Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular‐cholangiocarcinoma.” These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. Conclusion: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (H epatology 2018;68:113‐126).